Absolute Contraindications BPC-157 is not recommended for patients with: Active cancer (any type) theoretical concern regarding angiogenesis promotion Pregnancy or breastfeeding insufficient safety data Known hypersensitivity to any component of the formulation Relative Contraindications (Require Individualized Assessment) History of cancer after completion of treatment, a waiting period and oncology clearance may be appropriate Autoimmune disease especially if active or requiring immunosuppressive therapy Anticoagulant use injection site bleeding risk, though minimal with proper technique Severe renal or hepatic impairment dosing adjustments may be needed Monitoring and Follow-Up Patients on BPC-157 protocols are monitored through: Baseline and follow-up labs including inflammatory markers (CRP, ESR), complete blood count, and metabolic panel Clinical assessments pain scores, range of motion, functional outcomes at 2-week, 4-week, and 8-week intervals Imaging when indicated repeat ultrasound or MRI for musculoskeletal conditions to document structural healing The Patient Journey: What to Expect For patients considering peptide therapy, understanding the timeline of response helps set realistic expectations

GHK-Cu and AHK-Cu are among the most directly studied peptides for hair-related effects, but the best option depends on the type of thinning and the intended treatment goal
Pregnancy and lactation: Avoid use during pregnancy or breastfeeding unless controlled human data show safety
Vitamins and Supplements: What to Know Before You Take Herbal SupplementsNot all herbs and supplements are safe, especially if you have certain medical conditions or take some drugs
Around the same time, army joe38 wrote in a review of the same product, I had a dangerous allergic reaction that needed to be treated with prednisone with this stuff
Med Phys 42:22612267 Szczykutowicz TP, Toia GV, Dhanantwari A, Nett B (2022) A review of deep learning CT reconstruction: concepts, limitations, and promise in clinical practice